NEW YORK – Apollomics said on Thursday that it has completed its merger with special purpose acquisition company Maxpro Capital Acquisition and has begun trading shares on the Nasdaq.
The merger, announced in September, also included a $23.65 million private investment in public equity (PIPE) financing raised in connection with the business combination. The firm is trading on the Nasdaq Capital Market under the ticker symbols APLM and APLMW. Apollomics will continue to be led by CEO Guo-Liang Yu and its other existing leaders. Yu said in a statement that the PIPE funding will help advance development of its oncology pipeline.
Apollomics has a number of targeted therapies in clinical development. Its lead candidate, c-MET inhibitor APL-101, is being studied in a Phase I/II trial in solid tumors harboring MET alterations. The firm is also developing APL-106 (uproleselan), an agent designed to target E-selectin, a molecule found on bone marrow cells, for acute myeloid leukemia. Its pipeline also includes candidates targeting ERBB1/2/4, PD-1, and PD-L1.
In 2020, the Foster City, California-based firm raised $124.2 million in Series C funding.